Report cover image

Europe Breast Cancer Screening Market, Forecast 2022-2027, Industry Trends, Share, Insight, Growth, Impact of COVID-19, Company Analysis

Publisher Renub Research
Published Feb 01, 2022
Length 270 Pages
SKU # RNBR16974291

Description

Europe Breast Cancer Screening Market, Forecast 2022-2027, Industry Trends, Share, Insight, Growth, Impact of COVID-19, Company Analysis

Europe Breast Cancer Screening Market is expected to be US$ 15.9 Billion by 2027. Breast cancer is the most typical cause of cancer-related mortality among women in Europe. It is more prevalent in European countries due to its modernized lifestyle; late pregnancies, high intake of alcohol because of these factors breast cancer incidence rates are high across European countries. As per the WHO (World Health Organization), the European region had 576,300 women breast cancer cases in 2020.

Therefore, regular breast screening is necessary to prevent malignancy. Breast cancer screening is a frequent examination to detect breast cancer. Early detection could provide timely treatment of patients, thereby decreasing the mortality rate. Breast cancer screening commonly involves MRI, mammography, scan, or ultrasound. Mammography is considered to be the most useful screening test for the detection of breast cancer.

Apart from this, factors responsible for Europe's breast cancer screening market's growth include the growing incidence of breast cancer and the increasing awareness about the early detection of breast cancer. Also, the ever-increasing government initiatives and support and robust research and development activities are prominent factors propelling the market growth. According to Renub Research report, Europe Breast Cancer Screening Industry will grow at a CAGR of 2.2% from 2021-2027

Mammography screening most considerable market in European Countries

Across European countries, mammography is one of the most prevalent breast cancer screening methods. It does not prevent cancer, but it can protect lives by finding cancer as early as possible. Since mammography is the classic gold technique used to screen breast cancer, European governments and other healthcare organizations are taking initiatives to screen women between the ages of 50 and 75. Further, digital breast tomosynthesis can raise the diagnostic accuracy of mammography and is used to assess equivocal or suspicious mammography findings. In 2019, Kheiron Medical Technologies launched Mia™, a breast cancer screening software product in Europe.

Europe Breast Cancer Screening Market Size was US$ 14.1 Billion in 2021

In this report European breast cancer screening market we have covered the following countries United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, and the Netherlands. Mammograms screening is the most widely used test to screen breast cancer in the UK. Further, digital mammography is becoming the preferred option of screening, even though the cost of the new technology is six times more elevated than the conventional systems. It presents the potential for significant advances in breast cancer diagnosis, including lower radiation dosages, reduced breast compression pressure, and improved detection. According to Renub Research Statistics, around 11,936.5 thousand UK population had breast cancer mammography screening in 2020.

COVID-19 Impact on Europe Breast Cancer Screening Market Growth Trends

The COVID-19 outbreak's has varied impact on the European breast cancer screening market. While breast cancer screening is integral to cancer control and prevention, many screenings have either been postponed due to the COVID-19 outbreak, leaving a vast number of European patients without access to recommended health care services. This disruption to breast cancer screening services has a significant impact on patients, health care practitioners, and health systems. As many hospitals and screening centers remain closed due to lockdowns in Europe, the demand for mammography procedures and MRI has to be subdued in the short term.

Competitive Landscape

AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd, and Sun Pharmaceutical Industries Ltd are some of the major market player in Europe cancer screening. Key companies working in the industry tirelessly focus on developing new screening methods for breast cancer. This is expected to drive the worldwide breast cancer screening industry growth during the forecast period.

Renub Research report titled “Europe Breast Cancer Screening Market by type (Mammography Screening, MRI Screening , Ultrasound Screening) by Country (United Kingdom, France, Germany, Italy, Spain, Switzerland, Norway, and the Netherlands) by Company Analysis (AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd)” provides a complete analysis of Europe Breast Cancer Screening Industry

Types - Market has been covered from 3 viewpoints

1. Mammography Screening
2. MRI Screening
3. Ultrasound Screening

Countries – 8 European Country Breast Cancer Screening Market has been Covered

1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Netherlands
7. Norway
8. Switzerland

Company Insights:

• Overview
• Recent Development
• Sales Analysis

Companies Covered in the Report:

1. AstraZeneca
2. Novartis
3. Sanofi
4. Pfizer
5. Bayer AG
6. GlaxoSmithKline plc
7. Hoffmann-La Roche Ltd.
8. Sun Pharmaceutical Industries Ltd

Table of Contents

270 Pages
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Europe Breast Cancer Screening Analysis
5.1 Europe Breast Cancer Market
5.2 Europe Breast Cancer Population
6. Europe Breast Cancer Screening Population
6.1 Mammography Screening Population
6.2 MRI & Ultrasound Screening Population
7. Europe Breast Cancer Screening Market
7.1 Mammography Screening Market
7.2 MRI Screening Market
7.3 Ultrasound Screening Market
8. Population Share – Europe Breast Cancer Screening Analysis
8.1 By Country – Mammography Screening Population
8.2 By Country – MRI & Ultrasound Screening Population
9. Market Share – Europe Breast Cancer Screening Analysis
9.1 Breast Cancer Screening Market Share
9.2 Mammography Screening Market Share
9.3 MRI Screening Market Share
9.4 Ultrasound Screening Market Share
10. United Kingdom
10.1 United Kingdom Breast Cancer Mammography Screening Population
10.2 United Kingdom Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
10.3 United Kingdom Breast Cancer Screening Market
10.3.1 Mammography Screening Market
10.3.2 Magnetic Resonance Imaging (MRI) Screening Market
10.3.3 Ultrasound Screening Market
11. France
11.1 France Breast Cancer Mammography Screening Population
11.2 France Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
11.3 France Breast Cancer Screening Market
11.3.1 Mammography Screening Market
11.3.2 Magnetic Resonance Imaging (MRI) Screening Market
11.3.3 Ultrasound Screening Market
12. Germany
12.1 Germany Breast Cancer Mammography Screening Population
12.2 Germany Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
12.3 Germany Breast Cancer Screening Market
12.3.1 Mammography Screening Market
12.3.2 Magnetic Resonance Imaging (MRI) Screening Market
12.3.3 Ultrasound Screening Market
13. Italy
13.1 Italy Breast Cancer Mammography Screening Population
13.2 Italy Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
13.3 Italy Breast Cancer Screening Market
13.3.1 Mammography Screening Market
13.3.2 Magnetic Resonance Imaging (MRI) Screening Market
13.3.3 Ultrasound Screening Market
14. Spain
14.1 Spain Breast Cancer Mammography Screening Population
14.2 Spain Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
14.3 Spain Breast Cancer Screening Market
14.3.1 Mammography Screening Market
14.3.2 Magnetic Resonance Imaging (MRI) Screening Market
14.3.3 Ultrasound Screening Market & Forecast
15. Switzerland
15.1 Switzerland Breast Cancer Mammography Screening Population
15.2 Switzerland Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
15.3 Switzerland Breast Cancer Screening Market
15.3.1 Mammography Screening Market
15.3.2 Magnetic Resonance Imaging (MRI) Screening Market
15.3.3 Ultrasound Screening Market
16. Norway
16.1 Norway Breast Cancer Mammography Screening Population
16.2 Norway Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
16.3 Norway Breast Cancer Screening Market
16.3.1 Mammography Screening Market
16.3.2 Magnetic Resonance Imaging (MRI) Screening Market
16.3.3 Ultrasound Screening Market
17. Netherlands
17.1 Netherlands Breast Cancer Mammography Screening Population
17.2 Netherlands Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
17.3 Netherlands Breast Cancer Screening Market
17.3.1 Mammography Screening Market
17.3.2 Magnetic Resonance Imaging (MRI) Screening Market
17.3.3 Ultrasound Screening Market
18. Porters Five Forces
18.1 Overview
18.2 Bargaining Power of Buyers
18.3 Bargaining Power of Suppliers
18.4 Degree of Competition
18.5 Threat of New Entrants
18.6 Threat of Substitutes
19. Company Analysis
19.1 AstraZeneca
19.1.1 Overview
19.1.2 Recent Development
19.1.3 Sales Analysis
19.2 Novartis
19.2.1 Overview
19.2.2 Recent Development
19.2.3 Sales Analysis
19.3 Sanofi
19.3.1 Overview
19.3.2 Recent Development
19.3.3 Sales Analysis
19.4 Pfizer
19.4.1 Overview
19.4.2 Recent Development
19.4.3 Sales Analysis
19.5 Bayer AG
19.5.1 Overview
19.5.2 Recent Development
19.5.3 Sales Analysis
19.6 GlaxoSmithKline plc
19.6.1 Overview
19.6.2 Recent Development
19.6.3 Sales Analysis
19.7 Hoffmann-La Roche Ltd.
19.7.1 Overview
19.7.2 Recent Development
19.7.3 Sales Analysis
19.8 Sun Pharmaceutical Industries Ltd
19.8.1 Overview
19.8.2 Recent Development
19.8.3 Sales Analysis
List Of Figures:
Figure-01: Europe – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-02: Europe – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-03: Europe – Breast Cancer MRI & Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-04: Europe – Forecast for Breast Cancer MRI & Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-05: Europe – Breast Cancer Screening Market (Million US$), 2017 – 2021
Figure-06: Europe – Forecast for Breast Cancer Screening Market (Million US$), 2022 – 2027
Figure-07: Europe – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-08: Europe – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-09: Europe – Breast Cancer MRI Screening Market (Million US$), 2017 – 2021
Figure-10: Europe – Forecast for Breast Cancer MRI Screening Market (Million US$), 2022 – 2027
Figure-11: Europe – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-12: Europe – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-13: United Kingdom – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-14: United Kingdom – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-15: United Kingdom – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-16: United Kingdom – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-17: United Kingdom – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-18: United Kingdom – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-19: United Kingdom – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-20: United Kingdom – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-21: United Kingdom – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-22: United Kingdom – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-23: France – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-24: France – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-25: France – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-26: France – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-27: France – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-28: France – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-29: France – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-30: France – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-31: France – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-32: France – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-33: Germany – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-34: Germany – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-35: Germany – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-36: Germany – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-37: Germany – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-38: Germany – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-39: Germany – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-40: Germany – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-41: Germany – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-42: Germany – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-43: Italy – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-44: Italy – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-45: Italy – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-46: Italy – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-47: Italy – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-48: Italy – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-49: Italy – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-50: Italy – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-51: Italy – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-52: Italy – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-53: Spain – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-54: Spain – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-55: Spain – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-56: Spain – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-57: Spain – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-58: Spain – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-59: Spain – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-60: Spain – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-61: Spain – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-62: Spain – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-63: Switzerland – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-64: Switzerland – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-65: Switzerland – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-66: Switzerland – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-67: Switzerland – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-68: Switzerland – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-69: Switzerland – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-70: Switzerland – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-71: Switzerland – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-72: Switzerland – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-73: Norway – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-74: Norway – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-75: Norway – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-76: Norway – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-77: Norway – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-78: Norway – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-79: Norway – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-80: Norway – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-81: Norway – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-82: Norway – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-83: Netherlands – Breast Cancer Mammography Screening Population (Thousand), 2017 – 2021
Figure-84: Netherlands – Forecast for Breast Cancer Mammography Screening Population (Thousand), 2022 – 2027
Figure-85: Netherlands – Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2017 – 2021
Figure-86: Netherlands – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population (Thousand), 2022 – 2027
Figure-87: Netherlands – Breast Cancer Mammography Screening Market (Million US$), 2017 – 2021
Figure-88: Netherlands – Forecast for Breast Cancer Mammography Screening Market (Million US$), 2022 – 2027
Figure-89: Netherlands – Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2017 – 2021
Figure-90: Netherlands – Forecast for Breast Cancer Magnetic Resonance Imaging (MRI) Screening Market (Million US$), 2022 – 2027
Figure-91: Netherlands – Breast Cancer Ultrasound Screening Market (Million US$), 2017 – 2021
Figure-92: Netherlands – Forecast for Breast Cancer Ultrasound Screening Market (Million US$), 2022 – 2027
Figure-93: AstraZeneca – Global Revenue (Million US$), 2017 – 2021
Figure-94: AstraZeneca – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-95: Novartis – Global Revenue (Million US$), 2017 – 2021
Figure-96: Novartis – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-97: Sanofi – Global Revenue (Million US$), 2017 – 2021
Figure-98: Sanofi – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-99: Pfizer – Global Revenue (Million US$), 2017 – 2021
Figure-100: Pfizer – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-101: Bayer AG – Global Revenue (Million US$), 2017 – 2021
Figure-102: Bayer AG – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-103: GlaxoSmithKline plc – Global Revenue (Million US$), 2017 – 2021
Figure-104: GlaxoSmithKline plc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-105: Hoffmann-La Roche Ltd. – Global Revenue (Million US$), 2017 – 2021
Figure-106: Hoffmann-La Roche Ltd. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-107: Sun Pharmaceutical Industries Ltd – Global Revenue (Million US$), 2017 – 2021
Figure-108: Sun Pharmaceutical Industries Ltd – Forecast for Global Revenue (Million US$), 2022 – 2027
List Of Tables:
Table-01: Europe – Mammography Screening Population Share by Country (Percent), 2017 – 2021
Table-02: Europe – Forecast for Mammography Screening Population Share by Country (Percent), 2022 – 2027
Table-03: Europe – MRI & Ultrasound Screening Population Share by Country (Percent), 2017 – 2021
Table-04: Europe – Forecast for MRI & Ultrasound Screening Population Share by Country (Percent), 2022 – 2027
Table-05: Europe – Breast Cancer Screening Market Share by Country (Percent), 2017 – 2021
Table-06: Europe – Forecast for Breast Cancer Screening Market Share by Country (Percent), 2022 – 2027
Table-07: Europe – Mammography Screening Market Share by Country (Percent), 2017 – 2021
Table-08: Europe – Forecast for Mammography Screening Market Share by Country (Percent), 2022 – 2027
Table-09: Europe – MRI Screening Market Share by Country (Percent), 2017 – 2021
Table-10: Europe – Forecast for MRI Screening Market Share by Country (Percent), 2022 – 2027
Table-11: Europe – Ultrasound Screening Market Share by Country (Percent), 2017 – 2021
Table-12: Europe – Forecast for Ultrasound Screening Market Share by Country (Percent), 2022 – 2027

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us